Human glyoxylate metabolism revisited: New insights pointing to multi‐organ involvement with implications for <scp>siRNA</scp>‐based therapies in primary hyperoxaluria
R. J. A. Wanders(Emma Kinderziekenhuis), Sander F. Garrelfs(Emma Kinderziekenhuis), Jaap W. Groothoff(University of Amsterdam), Eduardo Salido(Universidad de La Laguna), Lisa J. Deesker(Emma Kinderziekenhuis)
Cited by 16
Related Papers
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis
|Nature Medicine|2011|834
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|509
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment
|Nephrology Dialysis Transplantation|2012|335
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope
|Nature Reviews Nephrology|2023|154
Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria
|Nephrology Dialysis Transplantation|2011|144